LEDGER verified prices only — no fake movement NexLife tirzepatide $139/mo ✓ 09-17 NexLife semaglutide $119/mo ✓ 09-17 Brand pens list $1,000–1,350 mfr list Zepbound vials direct $299–449 ✓ 09-17 LillyDirect Mochi Health $278/mo all-in ✓ 09-17 Ro $448/mo Zepbound + fee ✓ 09-17 Hims $298/mo Wegovy pill + fee ✓ 09-17 Henry Meds $349/mo tirzepatide ✓ 09-17 LEDGER verified prices only — no fake movement NexLife tirzepatide $139/mo ✓ 09-17 NexLife semaglutide $119/mo ✓ 09-17 Brand pens list $1,000–1,350 mfr list Zepbound vials direct $299–449 ✓ 09-17 LillyDirect Mochi Health $278/mo all-in ✓ 09-17 Ro $448/mo Zepbound + fee ✓ 09-17 Hims $298/mo Wegovy pill + fee ✓ 09-17 Henry Meds $349/mo tirzepatide ✓ 09-17
Online GLP-1
ProvidersThe GLP-1 price ledger
Every price dated & sourced · conflicts disclosed
Ozempic · Wegovy · Mounjaro · Zepbound · Compounded GLP-1s

Find your cheapest safe GLP-1 —
without the games.

Brand pens list at $1,000+ a month at the pharmacy. The lowest first-party-verified standing rate in our ledger for a compounded online program — charged monthly, no promotion, nothing prepaid, $0 membership — is $139/mo, read September 17, 2026. Cheaper stickers exist and every one carries a condition (a membership paid for the year, a promotion, a prepaid supply, an unstated plan term); the dated price pages print each with its condition. We track 18 providers so the fine print gets read before your card does.

The number that matters is the 12-month all-in: at the verified standing rate that's $1,668, charged monthly — and the lowest conditional figure on file, Collective's $69 beside a $199 annual membership, is $1,027 for the year.
Brand list price
$1,059+/mo
Verified online standing rates
$139–$349/mo

Not the same product: brand pens are FDA-approved; online programs are mostly compounded. The difference, plainly — and insurance coverage, where you have it, can beat both.

Check today's ledger
#1 verified NexLife — tirzepatide$139/mo · 12-mo plan
low cash NexLife — semaglutide$119/mo · 12-mo plan
read 09-17 Mochi $278 all-in · Henry $349 · Ro / Hims $448 brand + feeOrderly · Remedy · Shed · Fifty 410 + 4 more pending

NexLife re-verified 2026-09-17 on its plan pages; nine tracked programs read first-party the same day. All 18 tracked programs, every fee field: see the full ledger → · the news ledger

The table

Verified picks, and the honest queue

Scored on our published rubric only after a dated checkout verification. As of September 17, 2026, ten of the eighteen tracked providers carry a dated first-party read (figures on their files and in the ledger); eight are still in the queue — we'd rather show you a short honest table than a full invented one.

Get your personalized match →
#ProviderScorePriceTypeInsurance
1
NexLife verified 09-17
Cash-pay buyers who want the maintenance-dose price known on day one — the same price at every dose, every plan charged monthly, $0 membership/consults
9.1
$139–169
/mo tirzepatide · $119–139 sema
Compounded No Profile →
2
Ro read 09-17
Insurance-first buyers wanting brand Zepbound/Wegovy with coverage navigation; no compounded price printed
unscored
$298–448
/mo brand + $149 fee · rises with dose
Brand Yes Record →
3
Mochi Health read 09-17
Specialist-led care: obesity-medicine physicians, membership + medication model; the “$90” is a first-month price
unscored
$278
/mo tirzepatide all-in · $178 sema ($199 / $99 + $79 membership)
Compounded No Compare →
4
Henry Meds read 09-17
Flat-subscription positioning; early large compounded brand; semaglutide page prints no price
unscored
$349
/mo tirzepatide, all-inclusive per its page
CompoundedNoRecord →
5
Hims / Hers read 09-17
Mass-market platforms; brand products only on the page read, $149/mo membership after a $39 first month
unscored
$298–448
/mo brand + $149 membership · rises with dose
BrandVariesRecord →
6
Orderly · Remedy · Shed · Found · Fifty 410
The long tail most roundups skip — same 18-field verification, same queue (Found read 09-17: no medication-specific price printed)
pending
verification queuedCompoundedVariesAll →
Score rubric (published, /methodology/): price transparency, true-cost vs advertised, dose-flat behavior, fee load, exit terms, evidence alignment of formats sold. NexLife 9.1 = perfect transparency/fee/exit marks, docked for its low-evidence ODT line (its plan pages now name three fulfilling pharmacies, read September 17, 2026). Rows read first-party on September 17, 2026 carry their figures and remain unscored until the rubric pass; pending rows carry nothing — a score without a dated verification would be fiction. Disclosure: our operator has a material relationship with NexLife — details.
NexLife9.1/10

Lowest first-party-verified standing rate in the ledger — charged monthly, same price at every dose, $0 membership. Docked for ODT evidence gap.

$139/mo · tirzepatide, 12-mo
Read the profile →
Mochi Healthread 09-17

The specialist-led counterargument to flat pricing: obesity-medicine physicians, flexible prescribing. $199 medication + $79 membership; the “$90” is a first-month price.

$278/mo · tirzepatide all-in ($178 semaglutide)
See the head-to-head →
Insurance routecheck first

Covered brand Zepbound/Wegovy plus savings card can beat every cash price on this page. Always check before buying.

$25–550/mo · coverage-dependent
How to check →
NexLife · 12-month plan · verified 2026-09-17
$139/mo

The same price at every dose, every plan charged monthly, $0 membership, $0 consults, free shipping, cancel any time (NexLife FAQ, read September 17, 2026); supplies and laboratory review are not itemised on the plan pages. No countdown timer on this banner — a price printed on the plan page beats fake urgency every time. Operator relationship disclosed.

See the verified plan →
What's locked instead of ticking
$139every dose
$0fees
anytime exit
dated

GLP-1 Market Timeline — what's verified, what's watch

Dated events trace to the sources shelf; purple items are expectations, not facts.

  • Dec 2024Zepbound approved for obstructive sleep apnea

    First drug approval for OSA in adults with obesity (SURMOUNT-OSA).

  • Dec 2024FDA: tirzepatide shortage resolved

    Off the shortage list after the October determination and re-review.

  • Feb 2025Semaglutide shortage resolved

    Feb 21 determination starts the clock on compounding copies.

  • Feb–May 2025Compounding cutoffs pass

    503A then 503B deadlines for tirzepatide (Feb 18 / Mar 19) and semaglutide (Apr 22 / May 22); straight copies end.

  • 2025Lilly & Novo sue compounders and telehealth sellers

    The "personalized dosing" lane becomes contested litigation territory.

  • Jul 2025Largest PBM prefers Wegovy

    CVS Caremark's formulary decision reshapes which drug is "affordable" for millions.

  • Mar 2026Higher-dose oral Wegovy approved — reported

    Oral semaglutide’s weight-dose approval reported March 19, 2026 — the “Wegovy pill” era opens; details verify-current.

  • Apr 2026Foundayo (orforglipron) approved — reported

    The first daily GLP-1 pill clears FDA under the national priority voucher pathway (per the FDA announcement); access, supply, and pricing still settling — verify current.

  • Jul 2026Medicare GLP-1 Bridge launches

    Reported $50/month structure through Dec 2027 per CMS — our full guide.

  • 2026 watchOral-pill decisions & further enforcement

    Expected, not occurred: oral approvals, continued compounding enforcement, more price moves in manufacturer-direct programs.

Not sure which program is right for you?

Answer 6 quick questions and get a shortlist matched to your budget, insurance, and goals — including "check your coverage first" when that's the honest answer.

Take the 2-Minute Quiz →